Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Background: A lower dosage of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukaemia (CML) has shown efficacy in managing short-term toxicity and maintaining a deep molecular response in patients who fail to achieve treatment-free remission. Method: From over 700 patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Lucia Vráblová, Hana Klamová, Ivana Skoumalová, Jana Navrátilová, Romana Janská, Jan Grohmann, Milena Holzerová, Edgar Faber
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Hematology, Transfusion and Cell Therapy
Subjects:
Chronic myeloid leukaemia
Tyrosine kinase inhibitor
Low dosage
Intermittent dosage
Haematologic toxicity
Kinase domain mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137924002712
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2531137924002712

Similar Items